GLP-1 Medications and Healthy Aging: A Guide to Smart, Safe Use in Older Adults

GLP-1 medications (short for glucagon-like peptide-1 receptor agonists) are a powerful and increasingly popular option for treating type 2 diabetes and obesity. These medications work by mimicking a natural hormone in the body that helps regulate blood sugar, curb appetite, and promote a feeling of fullness. These treatments have exploded in use over the last few years. While studies have shown these medications have dramatic health benefits, there are important considerations when older adults start a GLP-1 medication. In this article, we'll review how GLP-1 medications work and their established and emerging benefits. We'll then discuss some specific considerations for older adults, and practical recommendations to discuss with a healthcare provider when beginning these medications.

How GLP-1 Medications Work

GLP-1 medications mimic the action of a natural hormone in the body, with the effect of:

• Encouraging the pancreas to release insulin when blood sugar levels are high

• Reducing another hormone (glucagon) that raises blood sugar

• Slowing down how quickly food leaves the stomach, which helps people feel full longer (early satiety)

• Acting on the brain region involved in regulating hunger and satiety

Together, these actions can lead to better blood sugar control, weight loss, and improvements in overall metabolic health.

Established and Emerging Health Benefits for Older Adults

Heart and Metabolic Health

Large clinical trials have shown that GLP-1 medications can help lower the risk of serious heart problems, especially in people with type 2 diabetes and other risk factors. Across three major trials—LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide)—the average participant age was approximately 65 years, making the findings highly relevant to seniors. Subgroup analyses, when done, further demonstrated that the cardiovascular benefits were sustained in individuals over 75 years old.

Kidney Protection

The studies referenced above and others also show that these medications also help protect kidney function. These benefits appear to apply to both individuals with diabetes and other populations, such as individuals with obesity and cardiovascular disease. The use of GLP-1 medications can slow both the onset and progression of chronic kidney disease.

Mobility and Joint Relief

By promoting weight loss, GLP-1 medications may reduce strain on joints, leading to improved symptoms of osteoarthritis and support better mobility. One study showed significant reduction in knee pain in people treated with semaglutide in addition to exercise and a reduced-calorie diet. This can be a meaningful improvement for seniors trying to stay active and independent.

Brain Health

Several areas of the brain have GLP-1 receptors, meaning that there is a potential that GLP-1 medications may have an effect on brain health. Early findings suggest these medications may reduce inflammation in the brain, improve how brain cells respond to insulin, lower oxidative stress and support the growth of new brain cells. The effects of GLP-1 medications have been studied on cognitive function, as well as people with Alzheimer's and Parkinson's disease and there have now been several studies looking at the effects of GLP-1 medications on major neurologic disorders. At this time, the results are mixed, and while there is theoretical support and some positive signal for benefit, definitive results are still lacking. The Evoke trials are much larger, ongoing trials that will provide more clarity on the benefits for people with early Alzheimer's.

Special Considerations for Older Adults

Weight Loss and Sarcopenia

GLP-1 medications are effective at reducing body weight, but in older adults, excessive weight loss can pose a serious risk of falls, fractures, functional decline, and loss of independence in daily activities. The major GLP-1 studies show that 40-60% of weight lost comes from lean body mass, not fat. This may sound alarming, but the nuance is that lean body mass includes muscle mass as well as organs, water content from fat, and bones, so it's an imperfect measure of muscle mass loss. Measuring muscle mass loss is more complex, typically using MRI scan, and some muscle mass loss is expected naturally when someone loses weight as the body does not need as much muscle to support itself as body weight decreases. When these factors are taken into account, the muscle loss is not so alarming. Still, experts recommend trying to preserve muscle mass during weight loss to the extent possible with resistance exercise training and a high protein diet, and monitoring for excessive weight loss while on these medications.

Gastrointestinal Considerations

GLP-1 medications have common side effects of nausea, vomiting, diarrhea and constipation. In older adults with recurrent gastrointestinal problems, unexplained weight loss, significant constipation, or undernutrition, these medications may not be the best option.

Diabetes Management

For individuals concurrently taking diabetes medications that can cause low blood sugar (hypoglycemia) like insulin or sulfonylurea medications, GLP-1 medications can increase the risk of hypoglycemic (low blood sugar) episodes as the medication begins to take effect.

Appetite and Nutritional Risk

Because GLP-1 medications reduce appetite and increase satiety, they can unintentionally worsen poor oral intake, especially in seniors with cognitive impairment or dementia, or other chronic illnesses that cause poor appetite. For these individuals, even a low dose may be poorly tolerated and could accelerate functional decline.

Practical Recommendations

Older adults should talk to their healthcare provider about whether the following strategies are appropriate to ensure safe and beneficial use of GLP-1 medications:

• Complete a comprehensive geriatric assessment prior to starting a GLP-1 medication, including weight history, nutritional status, history of gastrointestinal problems, current medications, cognitive and functional status

• Monitor nutritional status: Carefully track weight and dietary intake while on a GLP-1 medication

• Encourage resistance-based exercise and adequate protein intake to preserve muscle mass and mitigate sarcopenia

• Re-evaluate medication appropriateness or consider dose adjustments if there is unintentional weight loss, new functional decline, or evidence of undernutrition or sarcopenia

• Increase the frequency of blood sugar monitoring to detect hypoglycemia, and adjust other diabetes medications accordingly when starting a GLP-1 medication

• Educate caregivers on recognizing signs and symptoms such as weight loss, hypoglycemia or reduced appetite that may signal the need to adjust therapy

Conclusion

GLP-1 medications offer established benefits for seniors with diabetes or obesity helping control blood sugar, reduce weight, and lower risks of heart and kidney disease. There are also potential neuroprotective benefits. With careful assessment, monitoring, and support, many seniors can benefit from these treatments while minimizing risks.